RSSDI Repository, Complications of Diabetes Demonstration RSSDI Repository, Complications of Diabetes Demonstration

Have a Question?

If you have any question you can ask below or enter what you are looking for!

  • Home/
  • Article /
  • Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.

Add to Collection
2011 Mar 12 Others Fist_Author_Year_PM

Full Author : ['Zinman, Bernard', 'Fulcher, Greg', 'Rao, Paturi V', 'Thomas, Nihal', 'Endahl, Lars A', 'Johansen, Thue', 'Lindh, Rebecka', 'Lewin, Andrew', 'Rosenstock, Julio', 'Pinget, Michel', 'Mathieu, Chantal']
Journal Title : Lancet (London, England)
Chapter : Section3
Journal Year : 2011
Cited by : Not Available

BACKGROUND: Insulin degludec is a new basal insulin that forms soluble multihexamer assemblies after subcutaneous injection, resulting in an ultra-long action profile. This study aimed to assess efficacy and safety of insulin degludec injected once a day .....

Keywords : ["randomise openlabel phase trial", "week versus insulin glargine", "ultralongacting basal insulin", "insulin degludec", "type diabetes", "three time", "patient", "day", "day"]